Addex Therapeutics Competitors
| ADXN Stock | CHF 0.04 -0.003 -7.89% |
Correlation: Addex Therapeutics vs COSMO Pharmaceuticals Summary
Poor diversification
Across the chosen horizon, ADXN and COPN show a correlation of 0.6 and fall into the Poor diversification bucket. Used correctly, the chart supports evaluation of whether adding the second position genuinely diversifies the first.
Moving against Addex Stock
The mean reversion tendency in Addex Therapeutics' price is a well-documented phenomenon that disciplined investors can exploit by identifying when price has diverged substantially from fundamental and historical anchors.
Addex Therapeutics Competition Correlation Matrix
Studying peer correlation around Addex Therapeutics gives investors a cleaner read on how much independent price behavior still exists across the competitive set. The business currently sits in the Healthcare sector and the Biotechnology industry. In practical terms, lower correlation may offer better diversification while higher correlation may leave the portfolio more exposed to one shared driver.
| -0.43 | -0.07 | 0.77 | 0.06 | SANN | ||
| -0.43 | 0.36 | -0.43 | 0.31 | NWRN | ||
| -0.07 | 0.36 | -0.22 | 0.64 | BSLN | ||
| 0.77 | -0.43 | -0.22 | 0.01 | EVE | ||
| 0.06 | 0.31 | 0.64 | 0.01 | COPN | ||
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
Surface-level performance for Addex Stock can mask how the business actually stacks up against its competitive set. A thorough review of Addex Therapeutics' risk-adjusted indicators provides a clearer picture of whether returns are being earned efficiently. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| SANN | 2.74 | 0.32 | 0.11 | 0.40 | 2.94 | 6.30 | 18.11 | |||
| NWRN | 2.80 | -0.24 | 0.00 | -0.29 | 0.00 | 6.60 | 16.79 | |||
| BSLN | 1.64 | 0.09 | 0.06 | 0.00 | 1.80 | 3.01 | 10.08 | |||
| EVE | 4.23 | 0.21 | 0.04 | 0.40 | 5.10 | 8.33 | 25.46 | |||
| COPN | 2.01 | -0.22 | 0.00 | -0.30 | 0.00 | 3.70 | 17.01 |
Addex Therapeutics Competitive Analysis
Addex Therapeutics competes directly with Santhera Pharmaceuticals, Newron Pharmaceuticals, and Basilea Pharmaceutica, and the financial data points to clear areas of divergence. On scale alone, Addex Therapeutics' 5.6 M valuation and 410,042 revenue define its weight class. Addex Therapeutics posts a -72.84% return on equity, reflecting current earnings headwinds. Revenue tilts toward Santhera Pharmaceuticals at 39.1 M compared with 410,042. Newron Pharmaceuticals holds the larger valuation at 291.4 M versus 5.6 M. Basilea Pharmaceutica converts shareholder equity more efficiently at 121.16% versus Addex Therapeutics at -72.84%.| Better Than Average | Worse Than Peers | View Performance Chart |
Addex Therapeutics Competition Peer Performance Charts
How to Analyze Addex Therapeutics Against Peers
Addex Therapeutics' peer analysis compares Addex Therapeutics with related companies to put valuation, quality, and risk metrics in context. This helps determine whether recent performance is company-specific or broadly sector-driven. A practical workflow includes:- Set a relevant peer group: Include direct competitors and close alternatives with comparable business exposure.
- Benchmark core financials: Compare profitability, growth, capital structure, and cash flow quality.
- Check valuation dispersion: Review whether Addex Therapeutics trades at a premium or discount versus peers and why.
- Evaluate risk profile: Compare volatility, drawdowns, and correlation to avoid false diversification assumptions.
- Document the thesis: Record where Addex Therapeutics leads or lags and what catalysts could close or widen the gap.
Peer Comparison Metrics & Methodology
The competition view for Addex Therapeutics includes both market-cap-weighted peers and natural business competitors, which are not always the same companies. Momentum comparison for Addex Therapeutics across peers can signal rotation when peers accelerate while Addex Therapeutics lags or vice versa. Standalone ratios for Addex Therapeutics can be misleading without the industry context that peer comparison provides. This view summarizes available data without implying outcomes. This section is designed to make peer positioning easier to interpret at a glance. For peer comparison, Addex Therapeutics has a market cap of 5.62 M, P/E of 39.53.
This section for Addex Therapeutics is built from periodic company reporting and market reference feeds, with harmonization applied to align reporting definitions. Values may update on different source schedules.